STAGE IVB LUNG CANCER AJCC V8

This study compares two treatments for lung lesions in people with non-small cell lung cancer, sarcoma, or colorectal cancer that has spread. One treatment uses microwave energy to heat and kill tumor cells, while the other is a small surgery to remove the tumor. Researchers want…

This early-phase trial tests two experimental drugs, sapanisertib and telaglenastat, in people with advanced non-small cell lung cancer that has spread to the brain or other areas. The main goals are to find the safest dose and see if the combination can shrink tumors or slow the…

This study tests whether adding tocilizumab to two standard immunotherapy drugs (ipilimumab and nivolumab) can reduce severe side effects while still fighting cancer. About 35 adults with advanced melanoma, non-small cell lung cancer, or bladder cancer will receive the combinatio…

This early-phase trial tests a drug called berzosertib combined with whole brain radiation for people with lung cancer that has spread to the brain. The main goal is to find the safest dose and see what side effects occur. About 15 adults with non-small cell, small cell, or neuro…

This early-phase study tests the safety and best dose of adding minnelide to the standard drug osimertinib for people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if the combination can better control tumor growth. About 8 adults with adv…

This early-phase study is for people with a specific kind of advanced lung cancer (ALK-positive non-small cell lung cancer) that has gotten worse despite prior ALK-targeted therapy. The trial combines two drugs: brigatinib (which blocks cancer growth signals) and bevacizumab (whi…

This study tests a new treatment combination for people with extensive-stage small cell lung cancer (ES-SCLC) who haven't had treatment yet. It combines a PARP inhibitor (olaparib), an immunotherapy drug (durvalumab), standard chemotherapy (carboplatin and etoposide), and radiati…

This early-phase study tests a new treatment for people with advanced non-small cell lung cancer that no longer responds to standard immunotherapy. The treatment uses specially engineered immune cells from umbilical cord blood, designed to better recognize and attack cancer cells…

This study tests a combination of two drugs, trametinib and pembrolizumab, in people with advanced non-small cell lung cancer that has returned or spread. The goal is to see how well this treatment works based on specific genetic markers in each patient's tumor. About 37 particip…

This study tests a combination of three drugs (docetaxel, ramucirumab, and pembrolizumab) in 30 people with advanced non-small cell lung cancer that has worsened after standard chemotherapy and immunotherapy. The goal is to see if this triple therapy is safe and works better than…

This study looks at whether adding surgery or radiation to the targeted therapy osimertinib can help people with advanced EGFR-mutant non-small cell lung cancer live longer without the disease getting worse. About 173 participants with stage IIIB or IV lung cancer will be randoml…

This study tests a combination of the CIMAvax vaccine (which targets a protein that helps tumors grow) and nivolumab (an immunotherapy that boosts the immune system) in people with advanced non-small cell lung cancer or squamous head and neck cancer. The goal is to find the best …

This early-stage trial tests a combination of all-trans retinoic acid (ATRA), a drug made from vitamin A, and atezolizumab, an immunotherapy, in 18 adults with advanced non-small cell lung cancer that has returned or spread. The main goal is to find the safest dose and understand…

This early trial tested a two-pronged approach for people with advanced ALK-positive non-small cell lung cancer. Participants first received a targeted drug (brigatinib), then local treatments like surgery or radiation to any remaining tumors. The goal was to see if this combinat…

This study tests whether adding an aurora kinase inhibitor to the standard drug osimertinib can better control advanced EGFR-mutant non-small cell lung cancer. About 32 adults with advanced or metastatic disease will receive the combination to find the safest dose and see if it s…

This early-phase study tests a new drug combination for people with advanced ALK-positive non-small cell lung cancer. The goal is to find the best dose and check safety of adding ensartinib to standard chemotherapy and bevacizumab. About 12 participants with stage IIIC or IV dise…

This study tests a drug called selpercatinib (LOXO-292) in people with a specific type of advanced or recurrent non-small cell lung cancer that has a RET gene fusion. The drug works by blocking enzymes that help cancer cells grow. About 124 participants will receive the treatment…

This study tests whether adding two antibody drugs (necitumumab and trastuzumab) to the standard pill osimertinib can shrink tumors in people with advanced EGFR-mutated lung cancer that has stopped responding to osimertinib alone. About 30 adults with stage IV non-small cell lung…

This study tests a combination of three drugs (niraparib, temozolomide, and atezolizumab) in people with advanced solid tumors or extensive-stage small cell lung cancer. The goal is to find the safest dose and see if the combination helps keep the cancer from growing longer than …

This study tests whether a lung cancer drug called atezolizumab can be safely given at home by a nurse, with doctor visits done by video call. It involves 5 adults with non-small cell lung cancer. The goal is to see if this home-based approach is practical and safe.

This study tests a new drug, pevonedistat, combined with standard chemotherapy (carboplatin and paclitaxel) in people with advanced non-small cell lung cancer that has already been treated with immunotherapy. The goal is to see if this combination can shrink tumors or stop them f…

This study tests a drug called AMG 510 in people with advanced lung cancer that has a specific genetic change (KRAS G12C). The drug targets this change to stop cancer growth. About 116 participants will receive the treatment to see if it shrinks tumors and how safe it is.

This study is testing a more focused radiation treatment for patients whose small cell lung cancer has spread to the brain. Instead of radiating the entire brain, which can cause side effects like memory problems, doctors use precise beams to target only the tumors. The goal is t…

This study tests an online program designed to improve social well-being and emotional support for women with non-small cell lung cancer. About 70 women currently receiving treatment will use mindfulness and compassion techniques to help manage distress. The goal is to see if the…

This early-stage trial looks at whether giving one very precise, high-dose radiation treatment after lung cancer surgery is safe and causes fewer side effects than the usual weeks of daily radiation. About 50 adults with non-small cell lung cancer who had surgery but still have s…

This study looks at whether a drug called anamorelin can help improve appetite and stop weight loss in people with advanced non-small cell lung cancer who have lost their appetite. About 25 participants will take either the drug or a placebo and share their experiences through in…

This study tests a nurse-led program designed to help people with advanced lung or gynecologic cancer cope with fears about their future. The program teaches practical ways to manage worry and unhelpful thoughts. The study includes 42 participants and focuses on whether the progr…

This study looks at whether doctors can consistently measure the chemotherapy drug paclitaxel in the blood of cancer patients. The goal is to see if this could help adjust doses to kill cancer while reducing nerve damage, a common side effect. About 22 adults with various solid t…

This study tests whether watching a short video helps people with metastatic cancer understand tumor genomic testing better. About 243 adults with cancer that has spread will watch the video and answer questions before and after. The goal is to see if the video improves knowledge…